clinical trial · NCT07735546
A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma
Umoja Biopharma·phase1·not yet recruiting·n = 100
Multiple Myeloma in RelapseMultiple Myeloma (MM)UB-VV500Rapamycin (sirolimus)
brief summary
This study is a Phase 1 dose-finding and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV500. The study will enroll patients with relapsed/refractory multiple myeloma.
started
Oct 1, 2026
primary completion
Dec 31, 2029
completion
Dec 31, 2029
last updated
Jul 30, 2026
official title
A Phase 1, Open-label, Multicenter Study of UB-VV500 With Rapamycin in Relapsed or Refractory Multiple Myeloma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol